SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Anabolic / Growth FactorResearch peptide

IGF-1 DES

aka DES(1-3) IGF-1

Short-acting IGF-1 analog with high local anabolic potency at injection sites.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

IGF-1 DES is IGF-1 with the first three amino acids removed, reducing IGFBP affinity and increasing local IGF-1R potency 5-10x while keeping a short systemic half-life.

Source
  • Recombinant expression
Forms
  • Subcutaneous or intramuscular injection

Mechanism of action

Binds IGF-1R with higher local potency and a shorter half-life than LR3, producing localized anabolic effects with less systemic exposure.

Pathways
  • · IGF-1R then PI3K then Akt then mTOR
Receptors
  • · IGF-1 receptor
Hormones
  • · IGF-1 (exogenous, short-acting)

How it acts on the body

DES(1-3) IGF-1 occurs naturally in trace amounts in milk and tissues but is also produced synthetically. The truncation makes it bind IGFBPs poorly while binding IGF-1R with several-fold higher affinity, so it is unusually potent locally and unusually short-acting systemically.

Because the systemic exposure window is brief, hypoglycemia risk is smaller than with LR3, but the local signal at the injection site is stronger — which is the basis for the (debated) practice of using it for site-specific hyperplasia.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Local IGF-1 activityIncreases
Higher receptor affinity than native IGF-1 at the injection site.
Systemic IGF-1Modulates
Short-lived systemic spike compared with LR3.
Growth hormoneDecreases
Mild pituitary feedback suppression.

Effects on the body

Increases
Localized protein synthesis
Supports
Satellite-cell recruitment

Organ system effects

Skeletal Muscle

Pronounced local anabolic signaling at injection site.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Strong local anabolic effect
  • Shorter systemic exposure than LR3

Potential side effects

Common
  • · Injection-site soreness
  • · Mild hypoglycemia
Rare
  • · Lethargy
Serious
  • · Tumor-growth concerns with chronic use

Drug interactions

Insulin
Additive hypoglycemia.
moderate

Pairing context

Often combined with
  • Resistance training around dosing
    Local hyperplastic stimulus aligns with mechanical load.
Avoid combining with
  • Active malignancy
    IGF-1R activation risk.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.